SCHEMBL3877326

SCHEMBL3877326

NC(=O)c1[nH]c2ccccc2c1-c1ccc(NC(=O)Nc2cccc(Cl)c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2 P11137 7/20 0.56
KDR P35968 5/20 0.55
PDGFRB P09619 3/20 0.55
MEN1 O00255 5/20 0.53
KMT2A Q03164 5/20 0.53
MAPT P10636 3/20 0.53
LMNA P02545 2/20 0.53
HTT P42858 2/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
KIT P10721 1/20 0.51
FLT3 P36888 1/20 0.51
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 1/20 0.50
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
NTRK1 P04629 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3879403 0.90 MAP2 (0.63) MAP2KDRPDGFRBKDM4EALDH1A1
SCHEMBL3879170 0.89 MAP2 (0.72) MAP2KDRPDGFRBKITFLT3
SCHEMBL3882131 0.87 MAP2 (0.56) MAP2KDRPDGFRBMEN1KMT2A
SCHEMBL3878470 0.87 MAP2 (0.56) MAP2KDRPDGFRBMEN1KMT2A
SCHEMBL3879349 0.87 KDR (0.73) MAP2KDRPDGFRBMEN1KMT2A
SCHEMBL3878947 0.87 MAP2 (0.56) MAP2KDRPDGFRBMAPTKIT
SCHEMBL1880291 0.87 MAP2 (0.59) MAP2KDRMEN1KMT2AMAPT
SCHEMBL3879937 0.84 KDR (0.55) MAP2KDRPDGFRBMEN1KMT2A
SCHEMBL3879419 0.84 KDR (0.55) MAP2KDRPDGFRBMEN1KMT2A
SCHEMBL3888761 0.84 KDR (0.74) MAP2KDRPDGFRBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566736-B2 Substituted indoles, compositions containing them, method for the production thereof and their use AVENTIS PHARMA S.A. (FR) 2009-07-28 US claimed
US-20070259910-A1 Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use AVENTIS PHARMA S.A. (FR) 2007-11-08 US claimed
EP-1841762-A1 SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE Aventis Pharma S.A. (FR) 2007-10-10 EP claimed
WO-2006061493-A1 SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AVENTIS PHARMA S.A. (FR) 2006-06-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259910-A1 Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use IDO1, RB1, IDO2 MAP2 1170/4885KDR 1690/4885PDGFRB 1177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.